Armune Bioscience
Founded Year
2008Stage
Acquired | AcquiredTotal Raised
$13.26MAbout Armune Bioscience
Armune BioScience is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Armune Bioscience Patents
Armune Bioscience has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/10/2015 | 5/23/2017 | Transcription factors, Autoimmune diseases, Prostate cancer, Syndromes, Oncology | Grant |
Application Date | 8/10/2015 |
|---|---|
Grant Date | 5/23/2017 |
Title | |
Related Topics | Transcription factors, Autoimmune diseases, Prostate cancer, Syndromes, Oncology |
Status | Grant |
Latest Armune Bioscience News
Nov 6, 2018
13:40 EST 6 Nov 2018 | BioPortfolio Reports Summary Armune BioScience Inc Armune BioScience, a subsidiary of Exact Sciences Corp is a medical device development company that develops and commercializes molecular prognostic and diagnostic tests. The company uses genomics and proteomics in cancer to identifying specific sets of genes or proteins. It develops protein signature based diagnostic tests for lung, prostate, and breast cancers that helps the physicians to differentiate between indolent and aggressive prostate cancer. Armune BioScience has also developed a phage protein microarray method to characterize autoantibody in cancer. The company is developing a prostate cancer diagnostic blood test having high sensitivity and specificity. It operates a research laboratory is located in Ann Arbor. Armune BioScience is headquartered in Kalamazoo, Michigan, the US. Armune BioScience Inc Medical Equipment Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News
Armune Bioscience Frequently Asked Questions (FAQ)
When was Armune Bioscience founded?
Armune Bioscience was founded in 2008.
Where is Armune Bioscience's headquarters?
Armune Bioscience's headquarters is located at 350 E. Michigan Avenue, Kalamazoo.
What is Armune Bioscience's latest funding round?
Armune Bioscience's latest funding round is Acquired.
How much did Armune Bioscience raise?
Armune Bioscience raised a total of $13.26M.
Who are the investors of Armune Bioscience?
Investors of Armune Bioscience include Exact Sciences, Apjohn Ventures, Grand Angels, University of Michigan and Accelerate Michigan Innovation Competition.
Who are Armune Bioscience's competitors?
Competitors of Armune Bioscience include Freenome and 3 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Armune Bioscience to Competitors
OncoTAB's technology was used to develop a blood test, Agkura Personal Score, which aids breast cancer detection in women with dense breast tissue.
Accuragen has developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in minuscule concentrations of circulating cell-free DNA (cfDNA) in blood. The Company's technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining proprietary techniques in molecular biology and computational algorithm for error suppression. With Accuragen's technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
20/20 GeneSystems has developed, validated, and undergone clinical testing of a blood test for the early detection of lung cancer. The test measures a panel of tumor biomarkers and utilizes a proprietary algorithm to combine the biomarker values to generate a unitary risk score.
Freenome uses computational biology and machine learning techniques to detect cancer in its early and treatable stages. It detects cancer at an early stage through a routine blood draw and uses a proprietary algorithm method for systematized early detection. It was founded in 2014 and is based in South San Francisco, California.
Owlstone Medical is a diagnostics company developing a breathalyzer for disease detection. It offers a breath biopsy platform to enable early detection across multiple cancers and other related conditions. The company was founded in 2004 and is based in Cambridge, U.K.
Liquid Genomics monitors patient therapy via blood-based molecular testing. Blood based testing is used to detect and quantify cancer gene mutations with high sensitivity using Digital PCR and or Allele Specific Blocker PCR for blood or tissue.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
